Invivyd Unveils Potential First-in-Class Measles Antibody, Boosts COVID-19 Trial Robustness
summarizeSummary
Invivyd announced significant progress in its REVOLUTION program for VYD2311, a COVID-19 antibody candidate, including upsizing the DECLARATION Phase 3 study by approximately 500 subjects to enhance statistical power, with top-line results now expected in Q3 2026. The company also aligned with the FDA on a pediatric study plan for VYD2311. Additionally, Invivyd revealed the discovery and advancement of VMS063, a novel, potentially first-in-class measles monoclonal antibody candidate. This news precedes an 8-K filing that will likely formalize the COVID-19 program updates. These developments are highly material for Invivyd, especially given the 'going concern' warning in its last 10-K, as they demonstrate robust pipeline progression and expansion into a new infectious disease market. Traders will be watching for further updates on recruitment rates for the DECLARATION study and the continued development of the VMS063 measles antibody.
At the time of this announcement, IVVD was trading at $1.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $381.5M. The 52-week trading range was $0.46 to $3.07. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.